scholarly journals Intravaginal immunization using a novel antigen delivery device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses

Retrovirology ◽  
2012 ◽  
Vol 9 (S2) ◽  
Author(s):  
PF McKay ◽  
JF Mann ◽  
A Pattani ◽  
VL Kett ◽  
K Malcolm ◽  
...  
2016 ◽  
Vol 4 (33) ◽  
pp. 5608-5620 ◽  
Author(s):  
Pan Li ◽  
Gaona Shi ◽  
Xiuyuan Zhang ◽  
Huijuan Song ◽  
Chuangnian Zhang ◽  
...  

Guanidinylated nanoparticles could act as effective immune adjuvants to elicit both potent antigen-specific cellular and humoral immune responses.


Vaccine ◽  
2007 ◽  
Vol 25 (41) ◽  
pp. 7065-7074 ◽  
Author(s):  
Andreas R. Kammer ◽  
Mario Amacker ◽  
Silvia Rasi ◽  
Nicole Westerfeld ◽  
Christel Gremion ◽  
...  

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Edmond J. Remarque ◽  
Bart W. Faber ◽  
Roberto Rodriguez Garcia ◽  
Herman Oostermeijer ◽  
Sodiomon B. Sirima ◽  
...  

AbstractPlasmodium falciparum apical membrane antigen 1 (PfAMA1) is a candidate malaria vaccine antigen expressed on merozoites and sporozoites. PfAMA1’s polymorphic nature impacts vaccine-induced protection. To address polymorphism, three Diversity Covering (DiCo) protein sequences were designed and tested in a staggered phase Ia/b trial. A cohort of malaria-naive adults received PfAMA1-DiCo adjuvanted with Alhydrogel® or GLA-SE and a cohort of malaria-exposed adults received placebo or GLA-SE adjuvanted PfAMA1 DiCo at weeks 0, 4 and 26. IgG and GIA levels measured 4 weeks after the third vaccination are similar in malaria-naive volunteers and placebo-immunised malaria-exposed adults, and have a similar breadth. Vaccination of malaria-exposed adults results in significant antibody level increases to the DiCo variants, but not to naturally occurring PfAMA1 variants. Moreover, GIA levels do not increase following vaccination. Future research will need to focus on stronger adjuvants and/or adapted vaccination regimens, to induce potentially protective responses in the target group of the vaccine.


2007 ◽  
Vol 81 (23) ◽  
pp. 13180-13190 ◽  
Author(s):  
Christiane Stahl-Hennig ◽  
Seraphin Kuate ◽  
Monika Franz ◽  
You S. Suh ◽  
Heribert Stoiber ◽  
...  

ABSTRACT The development of needle-free vaccines is one of the recently defined “grand challenges in global health” (H. Varmus, R. Klausner, R. Klausner, R. Zerhouni, T. Acharya, A. S. Daar, and P. A. Singer, Science 302:398-399, 2003). To explore whether a natural pathway to the inductive site of the mucosa-associated lymphatic tissue could be exploited for atraumatic immunization purposes, replication-deficient viral vector vaccines were sprayed directly onto the tonsils of rhesus macaques. Tonsillar immunization with viral vector vaccines encoding simian immunodeficiency virus (SIV) antigens induced cellular and humoral immune responses. Viral RNA levels after a stringent SIV challenge were reduced, providing a level of protection similar to that observed after systemic immunization with the same vaccines. Thus, atraumatic oral spray immunization with replication-deficient vectors can overcome the epithelial barrier, deliver the vaccine antigen to the mucosa-associated lymphatic tissue, and avoid induction of tolerance, providing a novel approach to circumvent acceptability problems of syringe and needle vaccines for children and in developing countries.


1997 ◽  
Vol 27 (11) ◽  
pp. 1285-1291 ◽  
Author(s):  
M. N. KOLOPP-SARDA ◽  
D. A. MONERET-VAUTRIN ◽  
B. GOBERT ◽  
G. KANNY ◽  
M. BRODSCHII ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document